134 related articles for article (PubMed ID: 36600109)
1. Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.
Muralidharan KK; Kowalski KG; Tong X; Haeberlein SB; Rajagovindan R; Nestorov I
J Pharmacokinet Pharmacodyn; 2023 Feb; 50(1):45-62. PubMed ID: 36600109
[TBL] [Abstract][Full Text] [Related]
2. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A
J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991
[TBL] [Abstract][Full Text] [Related]
3. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population.
McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R
J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561
[TBL] [Abstract][Full Text] [Related]
4. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
Wessels AM; Dowsett SA; Sims JR
J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
[TBL] [Abstract][Full Text] [Related]
6. Stages of Objective Memory Impairment Predict Alzheimer's Disease Neuropathology: Comparison with the Clinical Dementia Rating Scale-Sum of Boxes.
Grober E; Qi Q; Kuo L; Hassenstab J; Perrin RJ; Lipton RB
J Alzheimers Dis; 2021; 80(1):185-195. PubMed ID: 33492286
[TBL] [Abstract][Full Text] [Related]
7. Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.
Lansdall CJ; McDougall F; Butler LM; Delmar P; Pross N; Qin S; McLeod L; Zhou X; Kerchner GA; Doody RS
J Prev Alzheimers Dis; 2023; 10(1):9-18. PubMed ID: 36641605
[TBL] [Abstract][Full Text] [Related]
8. Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil.
Samara M; Levine SZ; Yoshida K; Goldberg Y; Cipriani A; Efthimiou O; Iwatsubo T; Leucht S; Furakawa TA
J Alzheimers Dis; 2021; 82(3):1075-1084. PubMed ID: 34120898
[TBL] [Abstract][Full Text] [Related]
9. Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD).
Oh ES; Rosenberg PB; Rattinger GB; Stuart EA; Lyketsos CG; Leoutsakos JS
J Am Geriatr Soc; 2021 Apr; 69(4):955-963. PubMed ID: 33382921
[TBL] [Abstract][Full Text] [Related]
10. Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease.
Jönsson L; Ivkovic M; Atri A; Handels R; Gustavsson A; Hahn-Pedersen JH; León T; Lilja M; Gundgaard J; Raket LL
Alzheimers Res Ther; 2024 Feb; 16(1):48. PubMed ID: 38424559
[TBL] [Abstract][Full Text] [Related]
11. Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
Jamalian S; Dolton M; Chanu P; Ramakrishnan V; Franco Y; Wildsmith K; Manser P; Teng E; Jin JY; Quartino A; Hsu JC;
CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):1029-1042. PubMed ID: 37101394
[TBL] [Abstract][Full Text] [Related]
12. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
[TBL] [Abstract][Full Text] [Related]
13. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.
Mallinckrodt C; Tian Y; Aisen PS; Barkhof F; Cohen S; Dent G; Hansson O; Harrison K; Iwatsubo T; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; von Hehn C; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A; Chen T; Budd Haeberlein S
J Prev Alzheimers Dis; 2023; 10(2):171-177. PubMed ID: 36946443
[TBL] [Abstract][Full Text] [Related]
14. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
[TBL] [Abstract][Full Text] [Related]
15. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
16. Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.
Samtani MN; Raghavan N; Novak G; Nandy P; Narayan VA
Neuropsychiatr Dis Treat; 2014; 10():929-52. PubMed ID: 24926196
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
18. Validity of the Clinical Dementia Rating Scale Sum of Boxes in Staging and Detection of Cognitive Impairment in Mexican Americans.
Julayanont P; DeToledo JC
J Geriatr Psychiatry Neurol; 2022 Jan; 35(1):128-134. PubMed ID: 33261535
[TBL] [Abstract][Full Text] [Related]
19. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
Yuksel JM; Noviasky J; Britton S
Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
[No Abstract] [Full Text] [Related]
20. 'Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
Dickson SP; Wessels AM; Dowsett SA; Mallinckrodt C; Sparks JD; Chatterjee S; Hendrix S
J Prev Alzheimers Dis; 2023; 10(3):595-599. PubMed ID: 37357301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
